World's Best Scientists 2026 revealed!

D-Index & Metrics

Economics and Finance

D-Index
39
Citations
6387
World Ranking
2429
National Ranking
286

Overview

Adrian Towse is affiliated with the Office of Health Economics in the United Kingdom. Their research primarily spans the field of Economics, Econometrics and Finance, with a focus on Economics and Econometrics. Towse's work also incorporates elements of General Health Professions, Public Health, Environmental and Occupational Health, Health, and Pharmacology.

The scientist's research extensively covers topics related to Health Systems, Economic Evaluations, and Quality of Life. Their work also addresses Pharmaceutical Economics and Policy, Healthcare Policy and Management, Healthcare cost, quality, and practices, Global Health Care Issues, Vaccine Coverage and Hesitancy, as well as the Economic and Financial Impacts of Cancer.

Towse has published in several prominent venues, including:

  • Value in Health
  • Cost Effectiveness and Resource Allocation
  • Frontiers in Health Services
  • Vaccine
  • BMC Health Services Research

Notable recent papers by Towse include:

  • Establishing a reasonable price for an orphan drug (2020, Cost Effectiveness and Resource Allocation)
  • Considering Severity in Health Technology Assessment: Can We Do Better? (2022, Value in Health)
  • Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop (2021, BMC Health Services Research)
  • Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy (2022, Applied Health Economics and Health Policy)
  • Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support (2020, Journal of Managed Care & Specialty Pharmacy)

Frequent collaborators in Towse's work include:

  • Mikel Berdud
  • Bernarda Zamora
  • Lotte Steuten
  • Michael Drummond
  • Andrew W. Bruce

Their research is characterized by an emphasis on economic evaluations within health care systems and a focus on cost-effectiveness analyses related to pharmaceuticals and broader health policy. Their contributions also address important issues such as pricing in orphan drugs and the assessment of severity in health technology evaluations.

Best Publications

  • Differential pricing for pharmaceuticals: reconciling access, R&D and patents.

    Patricia M. Danzon;Adrian Towse

  • Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

    Louis P. Garrison;Adrian Towse;Andrew Briggs;Gerard de Pouvourville

  • Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.

    Marc L. Berger;Nancy Dreyer;Fred Anderson;Adrian Towse

  • Learning from Thailand's health reforms

    Adrian Towse;Anne Mills;Viroj Tangcharoensathien

  • Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement

    Patricia M. Danzon;Andrew W. Mulcahy;Adrian K. Towse

  • The R&D Cost of a New Medicine

    J. Mestre-Ferrandiz;J. Sussex;Adrian Towse

  • Value-based differential pricing: efficient prices for drugs in a global context.

    Patricia M Danzon;Adrian K Towse;Jorge Mestre-Ferrandiz

  • Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

    Eric Faulkner;Lieven Annemans;Lou Garrison;Mark Helfand

  • A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]

    Louis P. Garrison;Peter J. Neumann;Richard J. Willke;Anirban Basu

  • Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

    Adrian Towse;Louis P. Garrison

  • Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

    Marco Barbieri;Michael Drummond;Richard Willke;Jeremy Chancellor

  • Using QALYs in cancer: a review of the methodological limitations.

    Martina Garau;Koonal K. Shah;Anne R. Mason;Qing Wang

  • Should NICE's threshold range for cost per QALY be raised? Yes.

    Adrian Towse

  • Cost-effectiveness Thresholds: Economic and Ethical Issues

    A. Towse;C. Pritchard;N. eds Devlin

  • Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis

    Louis P. Garrison;Sachin Kamal-Bahl;Adrian Towse

  • Operationalizing value-based pricing of medicines : a taxonomy of approaches.

    Jon Sussex;Adrian Towse;Nancy Devlin

  • Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.

    Bengt Jönsson;Grace Hampson;Jonathan Michaels;Adrian Towse

  • Gene therapy: evidence, value and affordability in the US health care system

    Grace Hampson;Adrian Towse;Steven D Pearson;William B Dreitlein

  • The Economics of Gene Therapy and of Pharmacogenetics

    Patricia Danzon;Adrian Towse

  • Orphan drugs policies: a suitable case for treatment

    Michael Drummond;Adrian Towse

  • Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis

    Louis P. Garrison;Adrian Towse;Brian W. Bresnahan

Frequent Co-Authors

Louis P. Garrison
Louis P. Garrison University of Washington
Michael Drummond
Michael Drummond University of York
Patricia M. Danzon
Patricia M. Danzon University of Pennsylvania
Nancy Devlin
Nancy Devlin University of Melbourne
Darius N. Lakdawalla
Darius N. Lakdawalla University of Southern California
David Parkin
David Parkin City, University of London
Helen McShane
Helen McShane University of Oxford
Charles E. Phelps
Charles E. Phelps University of Rochester
Anirban Basu
Anirban Basu University of Washington
Mark V. Pauly
Mark V. Pauly University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Advancing your education in Economics and Finance opens doors to diverse online degrees that complement and expand your expertise. Many students pursue a data analytics master's degree online, building critical skills in interpreting and leveraging financial data—highly valued by employers in today’s data-driven environment.

For those aiming to lead teams and drive organizational change, an online master's degree in organizational leadership can be a strategic next step. This degree strengthens your management capabilities, preparing you for leadership roles within financial institutions or corporate settings.

Another in-demand option is a business intelligence masters, which focuses on utilizing advanced analytical methods to improve business decision-making. This pathway is ideal for those interested in harnessing technology to uncover trends and strategies within financial markets.

If you’re seeking broad business acumen with added flexibility, consider a flexible mba no gmat. These programs allow you to earn a prestigious MBA without entrance exam barriers, paving the way for senior management roles in the finance sector.

Best Scientists Citing Adrian Towse

Trending Scientists

Recently Published Articles